A randomised clinical trial investigating the effect of indapamide versus placebo in
Studied treatment | indapamide 2.5 mg/d |
Control treatment | placebo |
Female (%) | 28% |
Age | 60 y |
Patients | |
Group sizes | 2841 / 2841 |
Inclusion criteria | men and women with history of TIA or stroke not severely disabled, irrespective of their blood pressure |
Exclusion criteria | neoplasm, rheumatic valvular disease, congestive cardiomyopathy, atrial fibrillation, secondary hypertension, hyperthyroidism, renal and hepatic disease, haemorrhagic disease, insulin dependent diabetes |
Inclusion SBP | nil |
Inclusion DBP | nil |
Number of selection measures | |
prior cardiovascular disease | |
prior stroke | |
heart failure | |
Diabetes (%) | |
prior myocardial infarction (%) |
Blindness | Double blind | Inclusion period | |
Follow-up duration | 2y | Centers | |
Lost to FU | ND | geographical localisation | China |
Primary endpoint | Design | Parallel groups | |
ArretTrt1 | ND | ||
Hypothese | Superiority | ||
baseline BP | 154/93 (80-280/50-150) | ||
Isolated systolic hypertension |
Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl) 1995;108:710-7 [PMID: 8575241] link to pdf add to Mendeley
Appears in following systematic reviews: